

Gilead Sciences – QuickView

13 February 2013

Investment summary: Oncology adds diversity

Gilead's investment case is understandably focused on its existing HIV franchise (\$8.1bn sales in FY12) and burgeoning expectations for its hepC portfolio. However, consensus estimates currently attribute little value to Gilead's oncology portfolio, despite the company spending \$1.3bn in the last two years to acquire late-stage cancer drugs. We therefore view the successful development of idelalisib (acquired through Calistoga for \$600m), simtuzumab (Arresto Biosciences for \$225m) and CYT387 (YM Biosciences for \$510m), as well as further potential oncology targets, as an emerging theme in bolstering and diversifying Gilead's offering.

CYT387 targets myelofibrosis...

Gilead's recently completed \$510m acquisition of YM adds a potentially unique JAK1/2 inhibitor for myelofibrosis (MF) – Phase I/II data from 166 patients has shown comparable spleen response activity to other JAK inhibitors, but a superior benefit on anaemia and transfusion dependency. With Gilead now in control we expect a more aggressive strategy for CYT387, posing a greater threat to Incyte's Jakafi, the only marketed JAK inhibitor in this setting. Gilead plans Phase III studies for CYT387 to start in H213, possibly going head-to-head with Jakafi, while further development for related myeloproliferative disorders (MDS, PV, ET) is also possible.

...and could complement simtuzumab

CYT387 could also prove to be of benefit in combination with simtuzumab (anti-LOXL2 MAAb), acquired through the \$225m purchase of Arresto in 2010. A [54-patient](#) Phase II study of simtuzumab+Jakafi in MF is ongoing and results in Q213 could have a bearing on CYT387 plans. Simtuzumab is also in or about to start Phase IIIb trials for pancreatic and colon cancers, as well as liver fibrosis, NASH, PSC and IPF.

Idelalisib leads the PI3K field

Gilead's third key cancer drug, idelalisib, was purchased through Calistoga in 2011 for \$600m (including milestones). A PI3K delta inhibitor, the product is in Phase III studies for CLL and iNHL and is now the most advanced agent in development.

Valuation: Pipeline success required to underpin \$68bn EV

Gilead's EV of \$68bn (\$2.7bn cash; \$8.4bn debt) compares to a consensus NPV (EvaluatePharma) of \$55bn, but this is derived almost entirely from the marketed HIV franchise and late-stage hepC portfolio. Successful cancer drug development would add another dimension to Gilead's investment case and help to underpin its EV.

Consensus estimates

Year End	Revenue (\$m)	PBT (\$m)	EPS (\$)	DPS (\$)	P/E (x)	Yield (%)
12/11	8,386	3,651	1.87	0.0	21.9	N/A
12/12	9,703	3,612	1.77	0.0	23.1	N/A
12/13e	10,621	4,427	1.86	0.0	22.0	N/A
12/14e	12,364	6,089	2.63	0.0	15.6	N/A

Source: Bloomberg

Price **\$40.83**
Market cap **\$62bn**

Share price graph



Share details

Code **GILD**
Listing **NASDAQ**
Sector **Pharma & biotech**
Shares in issue **1.52bn**

Business

Gilead Sciences is a US pharmaceutical company primarily focused on the development and commercialisation of anti-viral products, particularly for HIV (Atripla/Truvada) and hepatitis C (sofosbuvir). Gilead also has an emerging oncology portfolio in mid-to-late stage clinical trials.

Bull

- Market dominant HIV franchise.
- HepC portfolio (sofosbuvir NDA in Q213) potential to dominate market.
- Strong cash flow (>\$750m average per quarter).

Bear

- HIV franchise (Viread) starts to lose market exclusivity in 2017.
- Increasingly sensitive to regulatory and commercial progress of sofosbuvir.
- HepC market opportunity may be overestimated.

Analysts

Christian Glennie +44 (0)20 3077 5727
Jason Zhang PhD +1 646 653 7027
healthcare@edisoninvestmentresearch.co.uk

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

EDISON INVESTMENT RESEARCH LIMITED

Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only.

DISCLAIMER

Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Registered in England, number 4794244, Edison Investment Research Limited is authorised and regulated by the United Kingdom Financial Services Authority. www.edisoninvestmentresearch.co.uk. Registered on the New Zealand Financial Service Providers Register, number 247505, Edison Investment Research (NZ) Limited is registered to provide wholesale and/or generic financial adviser services and is regulated by the New Zealand Financial Markets Authority.

London +44 (0)20 3077 5700
Lincoln House, 296-302 High Holborn
London, WC1V 7JH, UK

New York +1 646 653 7026
245 Park Avenue, 24th Floor
NY 10167, New York, US

Wellington + 64 4894 8555
Level 15 HP Tower, 171 Featherston St
Wellington 6011, NZ

Sydney +61 (0)2 9258 1162
Level 33, Australia Square, 264 George St,
Sydney, NSW 2000, Australia